), can each be implicated with a specific component of these disease processes. The apoB moiety is similar in molecular weight and amino acid composition to apoB in low-density lipoprotein (LDL), the major carrier of cholesterol in the blood.
L ipoprotein[a] (Lp[a]) is a lipoprotein whose
plasma concentration contributes to the risk of both cardiovascular (CVD) and cerebrovascular (CBD) disease. Lp [a] has been shown to be a risk factor for these conditions in adults, independent of age, diet, physical activity, smoking status, ethanol consumption, and gender. 1 ' 2 The two major apoproteins present in Lp [a] , apolipoprotein B (apoB) and apolipoprotein[a] (apo [a] ), can each be implicated with a specific component of these disease processes. The apoB moiety is similar in molecular weight and amino acid composition to apoB in low-density lipoprotein (LDL), the major carrier of cholesterol in the blood.
- 3 and restenosis of coronary artery vein grafts. 6 These associations have been observed in both white and Asian populations, primarily in middleaged or older men. The subjects in these studies have generally presented with evidence of specific cardiac or cerebrovascular conditions. In most studies examining the association of Lp[a] with atherosclerotic disease, coronary atherosclerosis 47 or atherosclerosis in the extracranial carotid arteries 8 has generally been detected during examinations of individuals who have had either an MI, angina, or ischemic stroke. Few studies have focused on Lp[a] as a risk factor for preclinical CVD or CBD.
The investigation reported here examines the putative association between Lp[a] apolipoprotein and atherosclerosis of the extracranial carotid arteries in asymptomatic individuals. A population-based sample of individuals with evidence of atherosclerotic wall thickening, based on carotid intima-media wall thickness measurements made using B-mode ultrasound, and without symptomatic CVD was selected from the Ath-erosclerosis Risk in Communities (ARIC) Study and compared with control subjects free of arterial wall thickening.
Methods
The ARIC Study, a prospective, multicenter investigation of atherosclerotic clinical events and noninvasively measured atherosclerosis, examined 15,800 individuals aged [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] years between 1987 and 1989 in four field centers. Three of these centers -Forsyth County, N.C.; Minneapolis, Minn.; and Washington County, Md. -examined a general population sample from the appropriate age range; the fourth center, Jackson, Miss., derived its population entirely from the black residents of Jackson. 9 Carotid artery wall thickness was measured in the ARIC Study by B-mode ultrasonogTaphy (Reference 10, manual 6; and References 11 and 12) by the technique of Pignoli et al. 13 Cases were selected as those subjects having a maximum carotid artery far-wall thickness >2.5 mm or bilateral thickening greater than the approximate 90th percentile of the ARIC cohort distribution (corresponding to 1.7 mm in the internal carotid artery, 1.8 mm in the carotid bifurcation, and 1.6 mm in the common carotid artery). Control subjects were chosen from those participants having a maximum far-wall thickness < 75th percentile at the far and near walls of each of the carotid segments and of the popliteal artery. Cases and control subjects were required to meet minimum visualization criteria of arterial wall boundaries on ultrasound. Each case was then matched to one control by race, gender, 10-year age group, study center, and a 6-month "window" of examination date. Cases and control subjects were excluded if they had any evidence of symptomatic CVD or CBD, as defined by a history of angina on effort, physician-diagnosed heart attack, transient ischemic attack or stroke, or intermittent claudication. These criteria, presented in greater detail elsewhere, 14 16 High-density lipoprotein (HDL) cholesterol was assayed by dextran sulfate-magnesium precipitation 17 ; LDL cholesterol was estimated from the Friedewald equation. 18 The measurement procedures used by the ARIC Study for data collection at field centers and the details of the central processing of measurements are reviewed elsewhere. 9 Complete information is presented in the ARIC Study Protocols, as follows: home interview and clinical/ demographic data in manual 2, other lipid laboratory determinations in manual 8, and clinical chemistry methods in manual 10. 10 Conditional logistic regression of the association of Lp[a] protein with case-control status 19 was performed using PROC PHREG 20 ; stratified analyses and descriptive statistics were generated with SAS 20 as well. Significance of the case-control mean differences for continuous independent variables was tested via paired t testing; the Mantel-Haenszel x 2 statistic was used for categorical independent variables. Testing of statistical interaction was accomplished by conditional maximum likelihood estimation.
Results

Case-Control Attributes
The 492 matched pairs examined in this study were a predominately white sample: 395 of the pairs were white versus 97 pairs who were black, consisting of 62% males (303 pairs) and 38% females (189 pairs). Mean Lp [a] protein values were significantly higher in cases than control subjects (110.8 versus 79.3 jig/mL, respectively). In general, cases were older (despite matching by 10-year age group), heavier, and had higher blood pressures than their respective control subjects ( Lp[a] protein distributional differences between racial groups are presented in Table 2 . Blacks, whether cases or control subjects, had higher Lp[a] protein levels than did whites (208.4 and 139.4 ^tg/mL in black cases and control subjects, respectively, compared with 89.5 and 66.2 /xg/mL, respectively, in white cases and control subjects). In addition, cases had higher Lp[a] protein values than control subjects in both racial groups. Although neither black nor white participants exhibited a completely normal Lp[a] protein distribution, the median value in blacks was closer to the mean than in whites. Table 3 shows the Spearman correlation coefficients of selected continuous variables presented in Table 1 for cases and control subjects; Spearman correlations are given to account for any deviation from normal distributions. Among control subjects, only LDL cholesterol and fibrinogen values were statistically significantly correlated with Lp[a] protein; at the lower Lp[a] protein levels found among control subjects, LDL was only Nonmissing mean-mean and mean-maximum carotid artery far-wall thickness measurements for case-control pairs are presented in Table 4 . These data indicate the effectiveness of the case-control selection criteria in identifying individuals with atherosclerosis as defined by B-mode ultrasound and control subjects free of carotid artery wall thickening. At all sites, cases had greater mean-mean and mean-maximum carotid intima-media far-wall thicknesses than their matched counterparts. Mean wall thicknesses were close to maximum values in control subjects, consistent with the absence of marked intima-media thickening in the control group. Conversely, mean far-wall thicknesses were considerably smaller than maxima among cases. Of all sites, the largest percent difference between cases and control subjects occurred at the carotid bifurcation and the internal carotid artery, sites with a predilection to atherosclerotic plaque formation. Table 5 shows the results of a series of statistical models predicting risk of atherosclerosis from known cardiovascular risk factors by using conditional logistic regression. The first model shows that the odds of being a case increased by approximately 50% with each 1-SD increase in the mean population value of Lp[a] protein; this relation was statistically independent of other lipoproteins, body mass index (not shown owing to a lack of association), ethanol consumption (not shown), fibrinogen, smoking status, and hypertension. Substitution of the apolipoproteins apoA-I and apoB for HDL and LDL, respectively, in this model yielded essentially the same results (odds ratio [OR] of 1.53, 95% confidence interval [CI] 1.23, 1.90). The next two models show the effects on the OR estimates of removing smoking and hypertension, respectively, from the multivariable model. These were the only two covariates that had any effect on the OR estimate of the Lp[a]-atherosclerosis association, but the ORs were not sufficiently changed by these covariates to be considered as important confounding factors; OR estimates for a larger sample may reveal significant changes between models. Since this was a largely white population that exhibited a rightskewed Lp[a]-protein frequency distribution, a logarithmic transformation of Lp[a] protein was performed; this transformation did not affect the OR estimate (not shown). Testing the above associations with data from the white subgroup only yielded analogous results and are, therefore, not presented here; a small sample size among black case-control pairs with complete labora- V<0.05. tory data (/i=84 pairs) limited the potential for racestratified analyses.
Odds Ratio Estimates and Assessment of Confounding
The OR estimate for the Lp[a] protein-carotid wall thickening relation remained constant in models that tested univariate adjustment for the risk factors included in the multivariable models; in particular, age adjustment within the age-matching categories had no effect on the estimate, consistent with previous reports that Lp [a] Table 5 are either atherogenic risk factors (total and LDL cholesterol), thjombogenic risk factors (fibrinogen), or both (smoking and hypertension). The OR estimates for risk factors measured as continuous variables, based on a 1-SD difference (fibrinogen and LDL), were of the same order of magni- 26 " 28 the extracranial carotid territory was also examined with Doppler ultrasonic imaging for prevalence of plaque. 8 Lp[a] was found to be an equally strong risk factor for cardiovascular and cerebrovascular outcomes 28 and a risk factor for plaque detected in the extracranial carotid arteries of patients with CBD. These studies, for the most part, dealt with individuals who presented with a chronic disease outcome. If Lp[a] is indeed a genetic risk factor that is present at comparable levels throughout adulthood, detection of preclinical CVD and CBD manifestations would allow for modification of more easily altered risk factors and behaviors. B-mode ultrasonography provides such information in a noninvasive, reliable manner.
B-mode ultrasound was used to assess atherosclerosis in this study. A noninvasive, low-risk procedure such as B-mode ultrasound is suitable for use in asymptomatic volunteers, thus reducing the potential for bias that is common in the selection of symptomatic study populations. Perceived symptoms and/or medical intervention in such populations can lead to a modification of the disease process or its antecedent risk factors. As documented on ARIC Study participants, B-mode ultrasound can be standardized for population-based, multicenter applications, achieving a high degree of reproducibility in scanning and reading.
11 ' 12 In addition, ultrasonography is more appropriate than angiography for measurement of early, subclinical atherosclerosis that may have little or no lumen involvement. Ricotta et al 29 compared the ability of B-mode ultrasonography and angiography to identify atherosclerosis and found B-mode superior in quantifying the extent of plaque formation. Quantitative imaging of the early stages of wall thickening permits observation of developing atherosclerosis rather than its outcome: advanced, and often complicated, lesions. Furthermore, B-mode ultrasound reduces the potential for misclassification that is inherent in identifying the absence of clinically manifest atherosclerotic disease in individuals who may or may not exhibit preclinical atherosclerosis. Because Lp [a] has both atherogenic and thrombogenic potential, investigation of preclinical atherosclerosis can address the impact of Lp[a] as an atherogenic agent before the occurrence of a CVD or CBD event.
The Lp[a] protein and LDL cholesterol are weakly correlated (r=0.12) among control subjects in this study and slightly more strongly correlated in cases (r=0.21), consistent with correlations found in the healthy population described by Guyton et al. 21 Although elevated Lp[a] concentrations are associated with increased CVD prevalence in hypercholesterolemics 23 -31 and among individuals with elevated LDL cholesterol levels, 4 the relation between Lp[a] protein and casecontrol status was not altered by LDL in the study presented here. In addition, the conditional logistic regression-parameter estimate obtained for the association between Lp[a] protein and atherosclerosis was unaffected by LDL.
The atherosclerosis cases in this study had significantly higher levels of several well-established cardiovascular risk factors, including total cholesterol, LDL cholesterol, triglycerides, blood pressure, age, and body mass 14 ; mean HDL cholesterol values were lower in cases. Cases were more likely than control subjects to be current smokers and were composed of a higher proportion of diabetics. Despite the highly significant differences in cardiovascular risk factor levels between cases and control subjects, Lp[a] protein remained a statistically independent predictor of atherosclerotic risk after multivariable adjustment for the other variables.
Although 43 Since only 27 individuals in our study were taking any kind of antihypercholesterolemic medication and only two of the cases were taking niacin, we did not test for these effects. The impact of antihypercholesterolemic therapy on the Lp[a] protein-atherosclerosis association remains to be tested in a larger population.
Significant differences in the mean Lp[a] protein concentrations exist between the black and white subjects in this study: 174.6 versus 77.8 iiglmL, respectively, with the black population exhibiting a more normal distribution than their white counterparts. These results are in agreement with those previously reported by Guyton et al 21 and Utermann 22 in both American and African black populations. Because the participants in the case-control study were matched by race in the design phase, we were unable to test for race as a confounding factor in the association between Lp[a] protein and atherosclerosis in multivariable modeling; however, race was not a significant effect modifier of this association.
Early reports of the properties of Lp[a] indicated no gender difference in the effect of Lp[a] on disease outcome, 44 although most of these studies dealt with middle-aged or older white men with hypercholesterolemia or heart disease. In the current study, the Lp[a]-atherosclerosis association did not differ by gender. Recent reports on noncontraceptive hormone replacement therapy in postmenopausal women indicate that estrogen users have lower mean Lp[a] values than nonusers 44 ; furthermore, women using progestin and estrogen in combination have lower Lp[a] values than either nonusers or estrogen users. 45 - 46 Again, these relations could not be tested here because of sample size, but future work in the full ARIC Study population will address the issue of menopause.
The case-control approach presented here has several advantages. Because our assessment of atherosclerosis by B-mode ultrasonography is based solely on the thickness of the carotid wall (without consideration of morphology), case selection criteria encompassed only extreme and/or bilateral arterial wall thickening as an index of atherosclerosis. Choosing cases from the highest decile of the population of wall-thickness distribution greatly reduces the possibility of wall thickening due to other nonatherosclerotic causes of wall thickening, such as medial hyperplasia, being misclassified as atherosclerosis. If participants without true atheroscle-rosis were selected as cases, their inclusion would only tend to underestimate the observed association between Lp[a] and intima-media wall thickening. Analogously, although control subjects were selected from <75th percentile of the maximum carotid artery wall thickness distribution, these individuals may have atherosclerosis in other arterial territories. This occurrence is unlikely but is of unknown frequency and must be considered in interpreting our results. This misclassification among controls, if present, would also tend to bias the reported OR toward unity.
Our study design excluded from analysis those individuals with prevalent CVD or CBD. Because of the association of CVD risk factors with these outcomes, this exclusion criterion eliminated three times more cases than control subjects from the study. Again, while this could tend to underestimate the effect of Lp[a] on case-control status by excluding some individuals who are more likely to have advanced atherosclerotic disease, this design was felt to be preferable to the alternative of incorporating the effect of medical intervention among cases with clinical manifestations. Conversely, choosing cases and control subjects based on measurements of carotid artery wall thickness offers no guarantee that atherosclerosis is systemic in the cases nor that carotid atherosclerosis will ultimately precipitate a stroke or be associated with an MI. A crosssectional study such as ours, examining the early phases of plaque formation, cannot establish that elevated levels of Lp[a] protein (or any risk factor, for that matter) will lead to progression of the disease process or will eventually lead to a CVD or CBD event. Follow-up of the ARIC cohort for changes in carotid wall thickness and clinical events will help to elucidate the role of Lp [a] 
